Proficio Capital Partners LLC lessened its stake in shares of Allergan PLC. (NYSE:AGN) by 8.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 832 shares of the company’s stock after selling 77 shares during the period. Proficio Capital Partners LLC’s holdings in Allergan PLC. were worth $208,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Checchi Capital Advisers LLC increased its stake in shares of Allergan PLC. by 10.3% in the second quarter. Checchi Capital Advisers LLC now owns 2,595 shares of the company’s stock worth $631,000 after acquiring an additional 242 shares during the last quarter. RiverPark Advisors LLC increased its stake in shares of Allergan PLC. by 6.9% in the second quarter. RiverPark Advisors LLC now owns 6,200 shares of the company’s stock worth $1,507,000 after acquiring an additional 400 shares during the last quarter. State of Wisconsin Investment Board increased its stake in shares of Allergan PLC. by 8.4% in the second quarter. State of Wisconsin Investment Board now owns 424,539 shares of the company’s stock worth $103,201,000 after acquiring an additional 32,930 shares during the last quarter. Morningstar Investment Services LLC increased its stake in shares of Allergan PLC. by 7.4% in the second quarter. Morningstar Investment Services LLC now owns 207,288 shares of the company’s stock worth $50,390,000 after acquiring an additional 14,306 shares during the last quarter. Finally, Parkside Investments LLC increased its position in Allergan PLC. by 5.0% during the second quarter. Parkside Investments LLC now owns 15,155 shares of the company’s stock worth $3,684,000 after buying an additional 720 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.
Allergan PLC. (AGN) opened at 223.07 on Friday. The company has a market capitalization of $74.57 billion, a PE ratio of 6.80 and a beta of 1.18. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The stock’s 50 day moving average is $232.72 and its 200-day moving average is $236.77.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter in the prior year, the business earned $3.35 EPS. The business’s quarterly revenue was up 8.8% on a year-over-year basis. On average, analysts expect that Allergan PLC. will post $16.25 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.25%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is 9.95%.
COPYRIGHT VIOLATION NOTICE: This article was first posted by BBNS and is the sole property of of BBNS. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://baseballnewssource.com/markets/proficio-capital-partners-llc-trims-position-in-allergan-plc-agn/1601000.html.
Several research firms have commented on AGN. Deutsche Bank AG reaffirmed a “buy” rating and issued a $262.00 price target on shares of Allergan PLC. in a research report on Tuesday. Wells Fargo & Company reaffirmed an “outperform” rating on shares of Allergan PLC. in a research report on Monday. Royal Bank Of Canada reiterated a “buy” rating and issued a $285.00 target price on shares of Allergan PLC. in a research note on Wednesday, September 6th. Cantor Fitzgerald reiterated a “hold” rating on shares of Allergan PLC. in a research note on Tuesday, August 29th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $400.00 target price on shares of Allergan PLC. in a research note on Tuesday, August 29th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $274.69.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with our FREE daily email newsletter.